PDF herunterladen
Semin Respir Crit Care Med 2012; 33(02): 191-198
DOI: 10.1055/s-0032-1311799
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

New Anticoagulants in the Treatment of VTE

Grégoire Le Gal
1   Université Européenne de Bretagne, Brest, France.
2   Université de Brest, EA3878 (GETBO) IFR 148, Brest, France.
3   CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France.
,
Dominique Mottier
1   Université Européenne de Bretagne, Brest, France.
2   Université de Brest, EA3878 (GETBO) IFR 148, Brest, France.
3   CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. Mai 2012 (online)

    Lizenzen und Reprints

Abstract

Low molecular weight heparins (LMWHs) and vitamin K antagonists make up the cornerstone of therapy for patients with venous thromboembolism (VTE) but have drawbacks making their use difficult in daily practice. Current research focuses on the development of new anticoagulant drugs that could be administered orally at a fixed dose, with fewer food and drug interactions and no need for monitoring or dose adjustment. Several new drugs are tested in noninferiority trials, either as a single-drug approach treatment (e.g., rivaroxaban or apixaban), or after an initial course of LMWH (e.g., dabigatran or edoxaban). Published clinical trials demonstrate that rivaroxaban and dabigatran are noninferior to conventional treatment in patients with VTE. Several issues remain challenging for physicians, such as the lack of antidote and of routinely available monitoring tests. To what extent new anticoagulant drugs will change clinical practice is not yet well defined. They may facilitate outpatient management of VTE. They might also improve the risk–benefit balance of prolonged anticoagulation and therefore modify the optimal duration of anticoagulation in VTE patients.

Keywords

venous thromboembolism - anticoagulants - therapeutics - review
 

  • References

  • 1 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1 (7138) 1309-1312
    PubMedGoogle Scholar
  • 2 Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. ; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6, Suppl) 141S-159S
    CrossrefPubMedGoogle Scholar
  • 3 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6, Suppl) 454S-545S
    CrossrefPubMedGoogle Scholar
  • 4 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. ; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6, Suppl) 160S-198S
    CrossrefPubMedGoogle Scholar
  • 5 Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; 123 (6) 837-844
    CrossrefPubMedGoogle Scholar
  • 6 Rodger M, Carrier M, Gandara E, Le Gal G. Unprovoked venous thromboembolism: short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev 2010; 24 (4–5) 171-178
    CrossrefPubMedGoogle Scholar
  • 7 Linkins LA, Weitz JI. New and emerging anticoagulant therapies for venous thromboembolism. Curr Treat Options Cardiovasc Med 2010; 12 (2) 142-155
    CrossrefPubMedGoogle Scholar
  • 7a Jungbauer L, Dobias C, Stöllberger C, Weidinger F. The frequency of prescription of P-glycoprotein affecting drugs in atrial fibrilation. J Thromb Haemost 2010; 8: 2069-2070
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 9 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 10 Schulman S, Baanstra D, Eriksson H , et al; RE-SONATE Study Group. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism [abstract]. J Thromb Haemost 2011; 9: S22
    PubMedGoogle Scholar
  • 11 Schulman S, Eriksson H, Goldhaber SZ , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism [abstract]. J Thromb Haemost 2011; 9: S731
    PubMedGoogle Scholar
  • 12 Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H. ; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349 (18) 1713-1721
    CrossrefPubMedGoogle Scholar
  • 13 Beyer-Westendorf J, Büller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?. J Thromb Haemost 2011; 9 (11) 2153-2158
    CrossrefPubMedGoogle Scholar
  • 14 Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152 (9) 578-589
    CrossrefPubMedGoogle Scholar
  • 15 Kovacs MJ, Kahn SR, Wells PS , et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. J Thromb Haemost 2010; 8 (9) 1926-1932
    CrossrefPubMedGoogle Scholar
  • 16 Lu G, DeGuzman FR, Lakhotia S, Hollenbach SJ, Phillips DR, Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors [abstract]. ASH Annual Meeting Abstracts 2008; 112: 983
    PubMedGoogle Scholar
  • 17 van Ryn J, Litzenburger T, Waterman A , et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models [abstract]. J Am Coll Cardiol 2011; 57: E1130
    CrossrefPubMedGoogle Scholar
  • 18 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
    CrossrefPubMedGoogle Scholar
  • 19 Samama MM, Martinoli JL, LeFlem L , et al. Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103 (4) 815-825
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 20 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 21 Camm AJ, Kirchhof P, Lip GY , et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19) 2369-2429
    CrossrefPubMedGoogle Scholar